Visiongain Research Reports

Title	Published	Price
Dr. Reddy's Market Outlook, Forecasts and Analysis to 2012 By: Visiongain Founded by Indian Scientist Dr Anji Reddy in 1984, the company has developed into a fast-growing international corporation, with headquarters in Hyderabad, Andhra Pradesh, India. During the fiscal year 2006, Dr. Reddy's was the third-largest \| more...	4/11/2007	$2,210.00
Cannabinoid Market Forecasts & Analysis to 2012 By: Visiongain With 4 drugs now in the marketplace (a 100% rise from 2 years ago), the cannabinoid market continues to grow. Attitudes to the drugs are changing ensuring greater market penetration, and the first cannabinoid blockbuster \| more...	3/22/2007	$2,210.00
GSK's Cervarix - a future blockbuster of 2007 By: Visiongain The number of blockbusters continues to increase. The number is set to increase to 112 in 2007. Of the products set to receive FDA approval this year and generate blockbuster status on an annual basis, \| more...	3/22/2007	$2,210.00
AMD Market Outlook to 2012 By: Visiongain AMD is the most common cause of vision loss in the developed world for those over 50 years of age. We estimate there are over 20 million cases in the US and Europe. Dry AMD \| more...	3/16/2007	$2,210.00
Mobile TV Analysis & Forecasts to 2012 By: Visiongain Visiongain believes that Mobile TV will be successful, however it will not be the "killer application" that some had believed it would be. Rather, the service is likely to be a stepping stone to a \| more...	3/13/2007	$2,210.00
The Global Rheumatoid Arthritis Market Forecasts to 2012 By: Visiongain In a market believed to approach 5 million people in the leading pharma markets, the market for rheumatic anti-inflammatory drugs is both profitable and set to increase due to new launches. The annual revenue to \| more...	3/9/2007	$2,210.00
The IMS Report Market Forecast to 2012 By: Visiongain Virtually every major telecom industry player must now be dealing with IMS. News of planned IMS-compatible products and services are arriving almost every day. Are you one of them? If you are testing IMS, then \| more...	3/2/2007	$2,210.00
Tissue Engineering & Stem Cell Technology Report 2007 By: Visiongain The market potential of this technology is so huge that revenues may be in excess of $10 billion by 2013. This is a market that you should be part of - NOW!! With a \| more...	2/28/2007	$2,210.00
Novartis Market Outlook, Forecasts and Analysis to 2012 By: Visiongain With headquarters in Basel, Switzerland, Novartis is recognised as being one of the strongest performing pharmaceutical companies in terms of sales, high revenue growth, acquisitions, breadth of portfolio, product launches and pipeline developments. In 2006 \| more...	2/27/2007	$2,210.00
Mobile WiMAX Market Forecasts to 2012 - With comparisons to LTE or 4G By: Visiongain Mobile wimax equipment which utilize beam-forming and MIMO technologies will become available towards the end of this year. Broadband wireless deployments using pre-802.16e compliant equipment have already begun. In Korea both KT and SK Telecom \| more...	2/21/2007	$2,210.00
Biotech Drug Delivery Systems - Key Company Intelligence & Market Outlook to 2012 By: Visiongain The two major problems for biotech drugs are their mode of delivery and relative instability. The majority of delivery methods for biological drugs involve injection, which is not necessarily ideal for most indications. As the \| more...	2/19/2007	$2,210.00
VoIP in Europe: Fixed & Wireless Market Outlook to 2011 By: Visiongain Wireless VoIP has been one of the loudest voices at the GSM Congress this year. As consumers get use to fixed wireless VoIP they are then turning to reduce their mobile bill through wireless VoIP. \| more...	2/13/2007	$2,210.00
The Autoimmune Inflammatory Bowel Disease Market Outlook to 2012 By: Visiongain 'The Autoimmune Inflammatory Bowel Disease Market Outlook to 2012' is a new report from visiongain providing analysis of the current and future market for IBD drugs across all major indications. Forecasts are given based on \| more...	2/6/2007	$2,210.00
Theranostics Report 2007-2012 By: Visiongain This report delivers to you a clear understanding of the commercial prospects of theranostics. The fusion of drug therapy and diagnostics, with the purpose of optimising efficacy and safety, as well as streamlining the process \| more...	1/31/2007	$2,210.00
Quad-play FMC strategies 2006-2011: Adding mobile services to the triple play package By: Visiongain Sky in the UK have already begun to prepare for the introduction of Quadruple play and its impact on their business. The opportunity of offering a bundled mobile, fixed line, broadband and TV solution was \| more...	1/17/2007	$4,422.00
World Market for Cancer Vaccines 2007-2012 By: Visiongain "Lung cancer vaccine to be tested" "New US bill requires cancer vaccine for girls" "Cancer vaccine too expensive" These are just some of the news headlines that have seen the world cancer vaccine market \| more...	1/17/2007	$2,210.00
UMA-Enabled Dual-Mode Handsets and 3G Femtocells 2007-2012: Market Analysis and Forecasts By: Visiongain Electronic Access - Global Site License $9,900.00 Yes Electronic Access - Single User The aim of UMA-enabled dual-mode handsets is that it enables you as a GSM mobile \| more...	1/5/2007	$2,210.00
Mobile consumer email: Where Blackberry challenges Hotmail and Gmail Publication Date By: Visiongain A major issue facing mobile consumer email is pricing. Mobile operators, particularly in Europe, are concerned that consumer email will impact upon SMS revenues. As a result of this fear, mobile operators have not promoted \| more...	12/15/2006	$2,210.00
Therapeutic Monoclonal Antibodies, 2006-2011 - Maximising the Growth Potential of a Stocked Pipeline By: Visiongain While the pharmaceutical as a whole is suffering from single digit growth, thin uninspiring pipelines and pressure from an ever-aggressive generics industry - not so for monoclonal antibody therapies. The market for monoclonal antibody treatments \| more...	12/7/2006	$2,210.00
Central and Eastern European (CEE) Developing Markets for Pharmaceuticals, 2006-2011 By: Visiongain Central and Eastern European (CEE) Developing Markets for Pharmaceuticals, 2006-2011 - Part 3 of Developing Markets - discusses prospects for the large developing market of Central and Eastern Europe. The other reports discuss Asia \| more...	11/23/2006	$2,210.00
Latin American Developing Markets for Pharmaceuticals, 2006-2011 By: Visiongain Latin American Developing Markets for Pharmaceuticals, 2006-2011, examines developing pharmaceutical markets critically through comprehensive research and analysis. Visiongain applied techniques such as financial forecasting, SWOT analyses and discussion of qualitative factors. Societal, political, economic and \| more...	11/16/2006	$2,210.00
Achieving Success In The Developing Asian Pharmaceutical Sector 2007-2011 By: Visiongain Will the economic growth in new Asian markets allow you to offset global problems? With the Japan market slow and stagnant what other countries in the region offer you the greatest opportunities and how can \| more...	11/9/2006	$2,210.00
Content Convergence 2006-2011: Shifting The Value Chain Dynamics By: Visiongain Consumers are changing the way they access digital content, demanding that they be able to access the same content through multiple CE devices and platforms. The move to this form of content convergence is being \| more...	11/9/2006	$2,210.00
Bioinformatics Report - The Forecasts and Future of The Market 2006-2011 By: Visiongain "Outsourcing defines future of Euro Bioinformatics market" "Jump on bioinformatics bandwagon" These are just two newspaper headlines that appeared today. Managing your data is critical to your organisation. You already know that. But is \| more...	10/26/2006	$2,210.00
Anti-addiction Therapies, 2006-2011 - The Pharmaceutical Industry’s Next Viagra? By: Visiongain More money is spent advertising alcohol than any other product. For some, it like gambling and cigerettes are pleasant distractions, yet for others they are the generators of unbearable cravings and the cause of considerable \| more...	10/19/2006	$2,210.00
Title	Published	Price

< prev 1 2 3 4 5 6 7 8 9 10 next >

Phone: 800.298.5699 (US) or +1.240.747.3093 (Int'l)
Hours: 7:00 a.m. to 7:00 p.m. EST Monday through Friday
Email: customerservice@marketresearch.com
Copyright © 1999-2009, All Rights Reserved, MarketResearch.com
11/23/2009 - 2